# The Staged Treatment in Early Psychosis Study

> **NCT02751632** · PHASE3 · COMPLETED · sponsor: **Orygen** · enrollment: 342 (actual)

## Conditions studied

- Psychotic Disorders
- Personality Disorders
- Clinical High Risk

## Interventions

- **BEHAVIORAL:** Support and Problem Solving Therapy
- **BEHAVIORAL:** Cognitive Behavioural Case Management
- **DRUG:** Fluoxetine
- **DRUG:** Placebo
- **BEHAVIORAL:** 3-monthly monitoring

## Key facts

- **NCT ID:** NCT02751632
- **Lead sponsor:** Orygen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2019-07
- **Final completion:** 2022-05
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02751632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02751632, "The Staged Treatment in Early Psychosis Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02751632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*